Title: Cannabis

In this episode, the Kaleidoscope team talked all things marijuana including the use of cannabidiol to treat marijuana dependence, the history and lore of the drug, and a major flaw in the marijuana supply informing US-based research.

Citations:

  • Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D., Thomas, E. M., Astbury, D., … & Bloomfield, M. A. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10), 865-874.
  • Schwabe, A. L., Hansen, C. J., Hyslop, R. M., & McGlaughlin, M. E. (2019). Research grade marijuana supplied by the National Institute on Drug Abuse is genetically divergent from commercially available Cannabis. bioRxiv, 592725.

Kaleidoscope team:

  • Dr Dawn N. Albertson

    Summarising Dawn’s academic trajectory is not easy but, roughly: behaviour, drugs, brains on drugs and then educating people about brains, behaviour, and drugs.

    View profile
  • Prof Sukhi S. Shergill

    A multilingual MD/PhD, Sukhi is a Professor of Psychiatry and Systems Neuroscience at the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London and a Psychiatrist

    View profile
  • Dr Derek K. Tracy

    Derek is the Medical Director of West London NHS Trust, and a senior lecturer and King's College London and University College London.

    View profile
  • Dr Dan W. Joyce

    Certified genius and MD/PhD wunderkid, Dan works at the Department of Psychiatry, University of Oxford and is a Consultant Psychiatrist with Oxford Health NHS Foundation Trust. Veggie, data head, and a research purist, Dan’s signature acerbic wit brings comedy and clarity to all things complicated.

    View profile